CD49b also known as integrin alpha-2, VLA-2 subunit alpha or collogen receptor. CD49b is a 1181 amino acid 130 kDa single pass type-1 transmembrane glycoprotein which forms a heterodimer with integrin beta-1 and mediates the adhesion of platelets and other cell types to the extracellular matrix.
| Inventor | Institute |
|---|---|
| Martin Humphries | University of Manchester |
| Cat. #: | 152485 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology;Cell signaling and signal transduction;Immunology |
| Application: | ELISA ; FACS ; IP |
| Target: | Integrin alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) |
| Reactivity: | Human |
| Clone: | 31H4 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Integrin Subunit Alpha 2; Alpha 2 Subunit Of VLA-2 Receptor; Platelet Membrane Glycoprotein Ia; CD49 Antigen-Like Family Member B; Collagen Receptor; CD49B; GPIa; Very Late Activation Protein 2 Receptor; Alpha-2 Subunit; Human Platelet Alloantigen System; Platelet Glycoprotein GPIa; VLA-2 Subunit Alpha; CD49b Antigen; HPA-5; VLA-2; VLAA2; BR |
|---|---|
| Product description: | CD49b also known as integrin alpha-2, VLA-2 subunit alpha or collogen receptor. CD49b is a 1181 amino acid ÄÂ?130 kDa single pass type-1 transmembrane glycoprotein which forms a heterodimer with integrin beta-1 and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Purified human b1 integrin preparation from HT1080 fibrosarcoma cell extract. |
| Myeloma used: | P3X63Ag8.653 |
| Target background: | CD49b also known as integrin alpha-2, VLA-2 subunit alpha or collogen receptor. CD49b is a 1181 amino acid 130 kDa single pass type-1 transmembrane glycoprotein which forms a heterodimer with integrin beta-1 and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Tanaka et al. 2012. Int J Oncol. 41(5):1837-44. PMID: 22923148. Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. Tanaka et al. 2012. Oncol Rep. 28(1):330-6. PMID: 22552543. Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells. Tanaka et al. 2010. Int J Oncol. 37(1):125-31. PMID: 20514404. Establishment and characterization of novel human uterine leiomyosarcoma cell lines. Tanaka et al. 2009. Int J Mol Med. 23(2):173-80. PMID: 19148540. Remodeling of the human endometrial epithelium is regulated by laminin and type IV collagen. Tanaka et al. 2008. Int J Mol Med. 22(5):581-7. PMID: 18949377. Autocrine/paracrine regulation of human endometrial stromal remodeling by laminin and type IV collagen. Tanaka et al. 2008. Oncol Rep. 20(1):13-23. PMID: 18575713. Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery. Tanaka et al. 2006. Oncol Rep. 15(4):939-47. PMID: 16525683. Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro. Tanaka et al. 2005. Oncol Rep. 14(4):941-8. PMID: 16142355. Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.